ICH S12: The Decision That Decides Whether Biodistribution Needs Its Own GLP Study

Until 2023, a gene therapy sponsor designing a biodistribution study was largely improvising — leaning on FDA's older considerations documents, EMA's expectations, and whatever the last program's CRO recommended, all of which disagreed at the margins. ICH S12, finalized at Step 4 on March 14, 2023, replaced that improvisation with actual criteria. The one sponsors ask about first — and the one with the clearest cost and timeline consequence — is whether biodistribution has to be its own study or can ride inside the GLP toxicology program already planned.

The combination question, and the rule that decides it

ICH S12 permits biodistribution studies to be conducted either as standalone studies or combined with pharmacology or toxicology studies — the guideline does not default to one design over the other. What it does specify is the constraint that makes the combined option workable: when biodistribution evaluation is folded into a toxicology study, the dose level used for the biodistribution assessment should be at or above the anticipated maximum clinical dose, but must not exceed the highest dose level used in the toxicology study itself. Programs where the pharmacologically active dose and the toxicology high dose sit close together can usually satisfy this in one study arm. Programs with a wide margin between the two, or with a toxicology high dose set primarily for safety-margin reasons, often cannot — and that mismatch is the practical reason a standalone biodistribution study still gets chosen even though the guideline allows combination.

What GLP actually has to cover

The GLP question splits the same way the combination question does. A standalone biodistribution study does not need to be Good Laboratory Practice compliant at all — ICH S12 accepts non-GLP standalone studies in principle. Combine biodistribution into a GLP toxicology study, though, and the in-life procedures and sample collection have to stay within that study's GLP compliance; you cannot carve out the biodistribution arm's dosing and necropsy from the GLP umbrella the rest of the study runs under. What does stay flexible even inside a combined GLP study is the biodistribution sample analysis itself — the qPCR or other quantification work does not have to be run under GLP. Sponsors who assume a combined design means every downstream analytical step needs GLP validation are over-scoping the work; sponsors who assume none of it does are under-scoping the in-life piece FDA will actually check against the study protocol.

• Injection site(s), gonads, adrenal gland, brain. Core sites for a first-pass distribution read.
• Spinal cord — cervical, thoracic, and lumbar segments. Named separately, not as a single pooled sample.
• Liver, kidney, lung, heart, spleen, blood. The standard systemic-clearance and off-target organ set.
• Product-specific additions. Peripheral nerves, dorsal root ganglia, cerebrospinal fluid, vitreous fluid, draining lymph nodes, bone marrow, and eyes/optic nerve, added where the route of administration or vector tropism makes them relevant.

Gonadal tissue is on the biodistribution panel because persistence there matters — not because a biodistribution study tells you whether integration happened. Why S12's scope exclusions are easy to miss

What biodistribution data still doesn't answer

The scope exclusion that trips up the most nonclinical plans is the one sponsors least expect: ICH S12 explicitly places evaluation of shedding, and assessment of genomic or germline integration, outside its scope. Both gonadal tissue and cerebrospinal fluid are on the recommended panel, and both are the same tissues a shedding or integration risk assessment would want — which is exactly why teams assume a biodistribution study answers those questions along the way. It does not. A vector detected in gonadal tissue by qPCR tells you the vector or transgene is present; it does not tell you whether integration into the germline occurred, which needs a separate assay, and it does not satisfy a shedding risk assessment, which FDA and EMA evaluate through their own viral vector safety considerations rather than through S12. Sponsors who plan one combined study to cover biodistribution, shedding, and integration in a single nonclinical workstream are planning around a guideline that was written to keep those three questions separate.

None of this is a reason to over-build the nonclinical package. It is a reason to make the standalone-versus-combined call deliberately, with the dose-level constraint checked first, rather than defaulting to whichever design the CRO proposes. A well-scoped biodistribution study that fits cleanly inside an existing nonclinical development package can save a full study arm; a poorly-scoped one that assumes coverage S12 doesn't provide creates a gap FDA or EMA will find at IND or CTA review, not before. If your gene therapy program is heading into IND-enabling studies and the biodistribution design hasn't been checked against these specific criteria, that is where advanced therapy nonclinical strategy pays for itself before the study starts, not after the data comes back short.